Vertex Pharmaceuticals Incorporated · VRTX · Next earnings

Vertex Pharmaceuticals Incorporated reports Thursday, Feb 11, 2027

VRTX reports after market close with consensus EPS at $4.23 and revenue at $3.50B. Last quarter: Vertex lifts 2026 outlook as CF franchise and newer products support growth

Reports After market close98 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $4.23 Calendar consensus
Consensus revenue $3.50B Calendar consensus
Report date Feb 11, 2027 Thursday, date estimated
Session After market close 98 days away

Where VRTX left off: FY2026 Q3

Full report

Vertex lifts 2026 outlook as CF franchise and newer products support growth

EPS surprise -1.2% Reported $4.76 vs $4.82
Revenue surprise +0.6% Reported $3.44B vs $3.42B
Stock move -1.0% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised 2026 revenue guidance to $13.15–$13.25 billion, from the prior quarter's $13.1–$13.2 billion range. Higher operating expenses are expected alongside integration and commercial investment.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Regulatory outcomes and timing for povitacept and accelerated-approval pathways remain uncertain.
  • Crinetics integration could bring execution challenges and added costs.
  • Adoption and seasonality in newer or infusion-based products could affect commercial performance.

Questions analysts left open

  • How IgG monitoring requirements could affect povitacept labeling.
  • What constitutes a successful AMPLITUDE outcome, including proteinuria versus eGFR measures.
  • Whether the JOURNAVX patient-support-program phase-out affects gross-to-net and revenue.
  • Manufacturing continuity for povitacept, including continuous processing.

Ask FN2 about VRTX next report

Transcript, numbers and history already loaded
What should I watch for in VRTX's next earnings report?How did VRTX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into VRTX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the VRTX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent VRTX quarters

All VRTX earnings
-1.0%FY2026 Q3+1.7%FY2026 Q2-1.3%FY2026 Q1+5.7%FY2025 Q4

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.